Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.52 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.51 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.51 |
| ▸ | CCR2 | P41597 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.50 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.50 |
| ▸ | RAF1 | P04049 | 3/20 | 0.49 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13876221 | 0.86 | EPHX2 (0.56) | TP53MAPK14EPHX2DDR1NR1H4 | |
| SCHEMBL13876172 | 0.80 | TSHR (0.59) | LMNAEPHX2MAPK1NLRP1ALOX5 | |
| SCHEMBL14456972 | 0.80 | MEN1 (0.55) | LMNATRPV1RAF1 | |
| SCHEMBL13876192 | 0.79 | MAPK14 (0.57) | TP53MAPK14LMNAEPHX2DDR1 | |
| SCHEMBL5645070 | 0.78 | LMNA (0.64) | TP53LMNAEPHX2MAPK1NLRP1 | |
| SCHEMBL13876232 | 0.77 | DDR1 (0.63) | MAPK14EPHX2DDR1NR1H4 | |
| SCHEMBL5646507 | 0.77 | LMNA (0.70) | LMNAEPHX2NR1H4MAPK1NLRP1 | |
| SCHEMBL13876171 | 0.75 | TSHR (0.61) | MAPK14LMNAEPHX2NR1H4MAPK1 | |
| SCHEMBL4614558 | 0.73 | MAPK14 (0.64) | MAPK14 | |
| SCHEMBL4614555 | 0.73 | MAPK14 (0.64) | MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099184-A1 | Substituted pyridineamide compounds useful as soluble epoxide hydrolase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-16 | — | — | US | disclosed |
| US-20090099184-A1 | Substituted pyridineamide compounds useful as soluble epoxide hydrolase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099184-A1 | Substituted pyridineamide compounds useful as soluble epoxide hydrolase inhibitors | EPHX1, EPHX2, NCEH1 | TP53 3483/4885MAPK14 2991/4885LMNA 2116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.